Neuromyelitis Optica Spectrum Disorder Clinical Trial
Official title:
A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT03002038 -
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04064944 -
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
|
Phase 2 | |
| Recruiting |
NCT05414487 -
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
|
||
| Not yet recruiting |
NCT05551598 -
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 2 | |
| Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT01845584 -
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
|
Phase 2 | |
| Completed |
NCT04660539 -
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 3 | |
| Recruiting |
NCT05504694 -
Ofatumumab in AQP4-IgG Seropositive NMOSD
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05346354 -
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
|
Phase 2/Phase 3 | |
| Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 | |
| Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|
||
| Completed |
NCT01500681 -
Maintenance Plasma Exchange for Neuromyelitis Optica
|
||
| Not yet recruiting |
NCT06374264 -
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
|
N/A | |
| Not yet recruiting |
NCT05891379 -
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
|
||
| Recruiting |
NCT05909761 -
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
|
||
| Completed |
NCT02276963 -
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
|
Phase 1 | |
| Terminated |
NCT04155424 -
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
|
Phase 2/Phase 3 | |
| Completed |
NCT02003144 -
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
|
Phase 3 | |
| Completed |
NCT03819413 -
Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital
|